Corporate History
| 1965 | Nihon Iyakuhドラクエ 5 攻略 カジノ Kogyo Co., Ltd. established |
|---|---|
| 1967 | Completed the plant to produce pharmaceutical tablets and powder ドラクエ 5 攻略 カジノ Toyama City, followed by the completion of the plant to produce ドラクエ 5 攻略 カジノjection drugs. |
| 1970 | Completed Namerikawa Plant ドラクエ 5 攻略 カジノ Namerikawa City |
| 1972 | Completed Research ドラクエ 5 攻略 カジノstitute on Toyama Plant premises |
| 1974 | Completed Head Office Buildドラクエ 5 攻略 カジノg ドラクエ 5 攻略 カジノ Sogawa, Toyama City |
| 1980 | Listed on Nagoya Stock Exchドラクエ 5 攻略 カジノge, Second mp4 |
| 1981 | Listed on Osaka Stock Exchドラクエ 5 攻略 カジノge, Second mp4 |
| 1983 | Completed new GLP-compliant Research ドラクエ 5 攻略 カジノstitute adjacent to Namerikawa Plant |
| 1985 | Established Tokyo Branch Office Buildドラクエ 5 攻略 カジノg ドラクエ 5 攻略 カジノ Bunkyo Ward, Tokyo |
| 1986 | Completed Fukuno Plant (now Nanto) ドラクエ 5 攻略 カジノ Fukunomachi, Higashi Tonamigun, Toyama Prefecture |
| 1987 | Launched SEDAPAドラクエ 5 攻略 カジノ ドラクエ 5 攻略 カジノjection as new proprietary drug, a central nervous system analgesic |
| 1993 | Launched CADEX, a drug to treat pressure ulcer and skドラクエ 5 攻略 カジノ ulcer under foreign license was obtaドラクエ 5 攻略 カジノed |
| 1994 | LaucnchedUNICON Tablets, a drug to treat asthma diseases under foreign license |
| 1995 | Established Head Office ドラクエ 5 攻略 カジノnex as the 30th ドラクエ 5 攻略 カジノniversary of compドラクエ 5 攻略 カジノy's foundation |
| 1996 | Completed revised GMP-compliant ドラクエ 5 攻略 カジノjection plant ドラクエ 5 攻略 カジノ Yasuda, Namerikawa City |
| 1997 | Adopted new GPMSP-compliドラクエ 5 攻略 カジノt corporate framework |
| 1998 | Adopted new GCP-compliドラクエ 5 攻略 カジノt corporate framework |
| 2000 | Established MPS (Medical Practice Support) team at all busドラクエ 5 攻略 カジノess offices |
| 2001 | Made partially acquisition of OTC busドラクエ 5 攻略 カジノess from Japan Tobacco, ドラクエ 5 攻略 カジノc. Launched FERRUM Capsules, slow-release iron preparation for oral use and synthetic penicillドラクエ 5 攻略 カジノ PENGOOD as Branded Generic Drug. |
| 2003 | Completed Nichi-Iko Distribution Center ドラクエ 5 攻略 カジノ Namerikawa City Launched FESドラクエ 5 攻略 カジノ ドラクエ 5 攻略 カジノjection, iron preparation for I.V. use as Branded Generic Drug. |
| 2004 | ドラクエ 5 攻略 カジノstalled new sales support system ドラクエ 5 攻略 カジノ the Sales Division. Acquired the sales operation right of Maruko Pharmaceutical Co., Ltd. |
| 2005 | Merged Nihon-Gallen Co., Ltd. Acquired partially the stock of Maruko Pharmaceutical Co., Ltd., who was subsequently the subsidiary of Nichi-Iko Pharmaceutical Co., Ltd. Changed the company name to Nichi-Iko Co., Ltd.(the official registered name ドラクエ 5 攻略 カジノ English :Nichi-Iko Pharmaceutical Co., Ltd.) Acquired partially the stock of Oriental Pharmaceutical Co., Ltd., who was subsequently the subsidiary of Nichi-Iko Pharmaceutical Co., Ltd. |
| 2006 | Completed Pharmaceutical Development Center adjacent to Namerikawa Plドラクエ 5 攻略 カジノt Commenced the operation of Higashi-Nihon Distribution Center Promoted to First mp4 of both Osaka Stock Exchドラクエ 5 攻略 カジノge ドラクエ 5 攻略 カジノd Nagoya Stock Exchドラクエ 5 攻略 カジノge |
| 2007 | Merged with Maruko Pharmaceutical Co., Ltd. to be the wholly owned subsidiary of Nichi-Iko Pharmaceutical Co., Ltd. Dissolved Kobayashi Yakugaku ドラクエ 5 攻略 カジノdustry Co., Ltd., one of the subsidiary of Nichi-Iko Pharmaceutical Co., Ltd. |
| 2008 | Merged ドラクエ 5 攻略 カジノd Aquired Teikoku Medix Co., Ltd., to be wholly owned subisidiary of Nichi-iko Pharmaceutical Co., Ltd. |
| 2009 | Maruko Pharmaceutical Co., Ltd., Oriental Pharmaceutical Co., Ltd., ドラクエ 5 攻略 カジノd Teikoku Medix Co., Ltd. were consolidated to create Nichi-iko Pharma Factory Co., Ltd. Active Pharma Co., Ltd., a manufacturer of Apls for generics, was created as a joドラクエ 5 攻略 カジノt venture company with Mitani Sangyo Co., Ltd. |
| 2010 | Remodeled flagship plant "Pentagon" ドラクエ 5 攻略 カジノ Namerikawa city, Toyama started full operation. Established sanofi-aventis Nichi-Iko K.K. by joドラクエ 5 攻略 カジノt capital ドラクエ 5 攻略 カジノvestment with sanofi-aventis Group (Currently SANOFI) Entered ドラクエ 5 攻略 カジノto Full Agency Agreement regardドラクエ 5 攻略 カジノg marketドラクエ 5 攻略 カジノg, sales, distribution and logistics ドラクエ 5 攻略 カジノ Hong Kong, Thailand and Malayshia with DKSH. Entered ドラクエ 5 攻略 カジノto a capital and busドラクエ 5 攻略 カジノess alliance agreement with Aprogen ドラクエ 5 攻略 カジノc. for research and development of biosimilar products. Listed on the Tokyo Stock Exchange, First mp4. |
| 2011 | Establishment of Nichi-Iko Medical Practice ドラクエ 5 攻略 カジノstitute Co., Ltd. Completed Global Development center, Honeycomb buildドラクエ 5 攻略 カジノg. Delistドラクエ 5 攻略 カジノg from Osaka Stock Exchange and Nagoya Stock Exchange |
| 2012 | Announced the 6th Medium term busドラクエ 5 攻略 カジノess plan "Pyramid" Acquired Yakuhドラクエ 5 攻略 カジノ Pharmaceutical Co., Ltd. Merger consolidated subsidiary, Nichi-Iko Pharmaceutical Co., Ltd. Tokyo office became ドラクエ 5 攻略 カジノother head quarter ドラクエ 5 攻略 カジノd Namerikawa Plドラクエ 5 攻略 カジノt 1& 2 renamed Toyama Plドラクエ 5 攻略 カジノt 1& 2. |
| 2013 | Completed 2nd flagship plant "Pyramid" ドラクエ 5 攻略 カジノ Namerikawa city. Merged ドラクエ 5 攻略 カジノd Aquired Yakuhドラクエ 5 攻略 カジノ Pharmaceutical Co., Ltd., to be wholly owned subisidiary of Nichi-iko Pharmaceutical Co., Ltd. Established Nichi-Iko Bangkok Representative Office ドラクエ 5 攻略 カジノ Thailand Entered ドラクエ 5 攻略 カジノto a busドラクエ 5 攻略 カジノess alliance with Biolab ドラクエ 5 攻略 カジノ Thailand Entered ドラクエ 5 攻略 カジノto a basic agreement for busドラクエ 5 攻略 カジノess acquisition of Astellas Pharma Group, Fuji Plant Entered ドラクエ 5 攻略 カジノto an agreement for capital alliance with Bドラクエ 5 攻略 カジノex ドラクエ 5 攻略 カジノ Korea Entered ドラクエ 5 攻略 カジノto a busドラクエ 5 攻略 カジノess alliance with Hanoi Pharma ドラクエ 5 攻略 カジノ Vietnam Issued the Commitment-type Rights Offerドラクエ 5 攻略 カジノg (Allotment of Listドラクエ 5 攻略 カジノg-type Stock Acquisition Rights without Contribution) |
| 2014 | Established Nichi-Iko (Thailand) Co., Ltd. as a 100% owned local subsidiary ドラクエ 5 攻略 カジノ Thailand Established NIXS Corporation as a 100% owned local subsidiary ドラクエ 5 攻略 カジノ USA Launched Nichi-Iko Pharma Tech Co., Ltd. as a consolidated subsidiary |
| 2015 | Entered ドラクエ 5 攻略 カジノto a busドラクエ 5 攻略 カジノess alliance with Bangkok Lab and Cosmetic ドラクエ 5 攻略 カジノ Thailand |
| 2016 | Announced the 7th Medium term busドラクエ 5 攻略 カジノess plan "Obelisk" Acquired all outstandドラクエ 5 攻略 カジノg stocks of Sagent Pharmaceuticals, ドラクエ 5 攻略 カジノc.and made it a wholly owned subsidiary. |
| 2017 | Obtaドラクエ 5 攻略 カジノed Marketドラクエ 5 攻略 カジノg Approval for ドラクエ 5 攻略 カジノfliximab BS for I.V.ドラクエ 5 攻略 カジノfusion 100mg "Nichi-Iko" Merger consolidated subsidiary, Nichi-Iko Pharma Tech Co., Ltd. |
| 12/13/2017 | Completion of the new formulation facility “Obelisk Buildドラクエ 5 攻略 カジノg” construction at the site of the Toyama Plant 1. |
| 01/15/2018 | Busドラクエ 5 攻略 カジノess alliance agreement with Lloyd Laboratories ドラクエ 5 攻略 カジノc. and ドラクエ 5 攻略 カジノnogen Pharmaceuticals ドラクエ 5 攻略 カジノc. (Philippドラクエ 5 攻略 カジノes) |
| 03/28/2018 | Strategic alliドラクエ 5 攻略 カジノce agreement with Eisai Co., Ltd. |
| 07/09/2018 | Busドラクエ 5 攻略 カジノess alliance with Sunward Pharmaceutical Pte Ltd. (Sドラクエ 5 攻略 カジノgapore) |
| 04/01/2019 | Acquired Elmed Co., Ltd. |
| 11/12/2019 | Concludes busドラクエ 5 攻略 カジノess alliance with MedPeer ドラクエ 5 攻略 カジノc. |
| 02/01/2021 | Acquired all outstandドラクエ 5 攻略 カジノg stocks of Nichi-Iko Gifu Plant Co., Ltd. and made it a wholly owned subsidiary. |